Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.36Innova Captab Ltd shows a strong financial profile, marked by exceptional growth and profitability. The company is rapidly expanding its sales and profits while maintaining very healthy margins and returns for its investors. Its financial stability is a key strength, as it operates with very little debt, reducing risks associated with borrowing. This allows the company to reinvest its earnings back into the business. A notable area of focus is the company's operational efficiency; while it is growing its assets significantly, turning those assets into revenue is a developing aspect. It also takes a considerable amount of time to collect payments from customers. The future outlook appears positive, driven by aggressive growth strategies, though it is dependent on the successful utilization of its substantial new investments.
Health Score : 7.36Innova Captab Ltd shows a strong financial profile, marked by exceptional growth and profitability. The company is rapidly expanding its sales and profits while maintaining very healthy margins and returns for its investors. Its financial stability is a key strength, as it operates with very little debt, reducing risks associated with borrowing. This allows the company to reinvest its earnings back into the business. A notable area of focus is the company's operational efficiency; while it is growing its assets significantly, turning those assets into revenue is a developing aspect. It also takes a considerable amount of time to collect payments from customers. The future outlook appears positive, driven by aggressive growth strategies, though it is dependent on the successful utilization of its substantial new investments.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
73.01
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
43.37
P/B RATIO
5.59
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
3.75
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
1.33
EV/EBITDA RATIO
25.29
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1068.1 as on Sep 1, 2026.
Growth Score : 10.00The company is in a phase of exceptional and robust expansion. It is achieving outstanding growth in revenue, operating profits, and net income, indicating strong market demand and effective operational scaling. This high growth is supported by a significant increase in the company's asset base, reflecting aggressive investment in its future. The earnings available to each shareholder are also growing at an excellent rate, signaling that this expansion is creating substantial value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 94.89 | 15.61 | 16.74 | 15.08 | 31.03 |
| Operating Profit Growth Rate | 77.78 | 18.75 | 35.09 | 20.78 | 30.65 |
| Earnings Per Share (EPS) Growth | 85.36 | -97.34 | 16.45 | 35.9 | 9.91 |
| Asset Growth Rate | 55.41 | 22.43 | 86.93 | 19.15 | 17.16 |
| Net Income Growth Rate | 88.24 | 6.25 | 38.24 | 36.17 | 10.16 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 7 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 10 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 20 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 21 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤2nd Feb 26
Q3 & 9M FY26 Earnings Conference Call
BULLISH SENTIMENT
Innova Captab Ltd. is an Indian pharmaceutical company specializing in contract development and manufacturing (CDMO) services, domestic branded generic formulations, and international exports. It focuses on various therapeutic segments, offering a comprehensive range of quality pharmaceutical products and services.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Innova Captab Ltd's P/E ratio (TTM) is 73.01, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Innova Captab Ltd's P/B ratio is 5.59, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Innova Captab Ltd's P/S ratio is 3.75, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Innova Captab Ltd's PEG ratio is 1.33.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Innova Captab Ltd's EV/EBITDA ratio is 25.29.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Innova Captab Ltd's ROE is 12.92%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Innova Captab Ltd's ROA is 13.23%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Innova Captab Ltd's ROCE is 15%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Innova Captab Ltd's operating margin is 14.91%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Innova Captab Ltd's net margin is 8.65%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Innova Captab Ltd's current ratio is 1.77.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Innova Captab Ltd's debt-to-equity ratio is 0.20.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Innova Captab Ltd's interest coverage ratio is 12.06.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Innova Captab Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Innova Captab Ltd's EPS is 9.91.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1068.10. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2005
Headquarters: Panchkula, Haryana
Core Offerings: Contract Development and Manufacturing (CDMO), Domestic Branded Formulations, International Branded Formulations/Exports, OTC Products
Stock Listing: NSE (INNOVACAP), BSE (544067)
Promoter: Lohariwala Family / Manoj Kumar Lohariwala & Suraj Kumar Lohariwala
Innova Captab was incorporated in 2005 and commenced commercial operations in 2006. Over the years, it expanded its manufacturing capabilities and product portfolio, establishing itself as a key player in CDMO and generic formulations. In 2021, it converted into a Public Limited Company, culminating in a successful Initial Public Offering (IPO) and listing on NSE and BSE in December 2023.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Contract Development and Manufacturing Organization (CDMO) | ~61% | Operating Profit |
| Domestic Branded Formulations | ~25% | Operating Profit |
| International Branded Formulations (Exports) | ~14% | Operating Profit |
Contract Development and Manufacturing (CDMO): Provides end-to-end manufacturing and development services for a diverse range of pharmaceutical formulations to other pharma companies, ensuring quality and regulatory compliance.
Domestic Branded Formulations: Manufactures and markets its own portfolio of branded generic medicines within India across multiple therapeutic areas like pain management, anti-infectives, and gastrointestinal diseases.
International Branded Formulations (Exports): Engages in the export of its branded generic products to various semi-regulated and emerging markets globally, catering to diverse healthcare needs.
Manoj Kumar Lohariwala: Chairman & Whole-time Director. Co-founder with over two decades of experience in the pharmaceutical industry, providing strategic direction and vision. Suraj Kumar Lohariwala: Managing Director. Co-founder with extensive operational and manufacturing expertise, driving efficient production and expansion.
No major subsidiaries reported.
Initial Public Offering (IPO) completed in December 2023. No major recent bonus issues, rights issues, or significant M&A on record since IPO.
The Innova Captab Ltd share price today is ₹1068.10 on NSE (INNOVACAP), as of 26 Sept 2026.
As of 25 Sept 2026, Innova Captab Ltd share price is ₹1068.10, with previous close ₹1068.10. Today's range is ₹1068.10 to ₹1068.10. The 52-week range is ₹622 to ₹1353.50.
As of today, Innova Captab Ltd's market cap is ₹6,109.53 crore (Mid Cap).
Innova Captab Ltd's current P/E ratio is 73.01, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 31.50.
Innova Captab Ltd's current P/B ratio is 5.59.
Innova Captab Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Innova Captab Ltd's EPS (TTM) is ₹9.91.
Innova Captab Ltd. is an Indian pharmaceutical company specializing in contract development and manufacturing (CDMO) services, domestic branded generic formulations, and international exports. It focuses on various therapeutic segments, offering a comprehensive range of quality pharmaceutical products and services.
Innova Captab Ltd is promoted by Lohariwala Family / Manoj Kumar Lohariwala & Suraj Kumar Lohariwala, holding 50.9% as of 25 Sept 2026.
Innova Captab Ltd is listed on NSE (INNOVACAP) and BSE (544067). Its next quarterly results are expected on May-June 2024 (for Q4 & FY24 results).
Quick Ratios
